Biocon, Asia’s premier biotechnology company, has introduced CANMAb (150 mg/ 440 mg), a biosimilar trastuzumab for the treatment of HER2-positive metastatic breast cancer in India. CANMAb, developed jointly by Biocon and Mylan under a global partnership, is the world’s first biosimilar version of Herceptin and is being introduced for the benefit of patients in India.
Breast cancer is the most prevalent cancer among Indian women ahead of cervical cancer and CANMAb will offer a high quality, more affordable option to breast cancer patients in India.
CANMAb is being manufactured at Biocon’s biologics facility in Bangalore and will be available to patients around the first week of February 2014. CANMAb will be available at about 25% discount to the current list price of the reference product in India, which is already significantly lower than its price in developed markets. In addition, CANMAb’s 150 mg formulation, priced at Rs 19,500/vial, will allow extra savings to patients as they can buy smaller quantities as per their requirement.
Biocon is India’s largest and Asia’s leading Biotechnology Company with a strategic focus on biopharmaceuticals and research services.
